Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2020 16:48 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Completes Offering of Special Warrants

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and...
November 11, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Third Quarter 2020 Results

TORONTO and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
November 09, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease

TORONTO and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
November 05, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Closes First Tranche of Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and...
October 30, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium

TORONTO and CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
October 29, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board

TORONTO and CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
October 23, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and...
October 21, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

TORONTO and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
October 13, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference

ProMIS’ proprietary drug discovery and development platform highlighted for ability to create novel antibodies, diagnostics and vaccine candidates for neurodegenerative diseases TORONTO and...
September 22, 2020 06:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease

TORONTO and CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...